Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021
• Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed orrefractory multiple
Reports
Gritstone Reports Second Quarter 2021 Financial Results and Business Update
GRANITE Phase 1/2 data of individualized neoantigen immunotherapy in advanced solid tumors accepted for mini-